New study aims to improve inhaler therapy for lung fungus patients
NCT ID NCT07530263
First seen May 13, 2026 · Last updated May 22, 2026 · Updated 4 times
Summary
This study looks at how well an inhaled antifungal drug (liposomal amphotericin B) reaches the lungs in people with chronic pulmonary aspergillosis, a long-term lung infection. About 18 adults will receive two different doses on separate days, then have special scans to see where the drug goes in the lungs. The goal is to find the best dose and delivery method to improve treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PULMONARY ASPERGILLOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Radboudumc
Nijmegen, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.